Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Protagonist Therapeutics's enterprise value was $7.94B on Nov 11, 2026, against $5.04B a year earlier. Over the last 5 years it ranged from $78.76M to $8.77B, with a median of $1.71B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $7.94B | +62.8% |
| 2025 | Dec 31, 2025 | $4.88B | +166.7% |
| 2024 | Dec 31, 2024 | $1.83B | +82.7% |
| 2023 | Dec 29, 2023 | $1.00B | +271.7% |
| 2022 | Dec 30, 2022 | $269.32M | -79.5% |
| 2021 | Dec 31, 2021 | $1.32B | +135.7% |
| 2020 | Dec 31, 2020 | $558.29M | +931.7% |
| 2019 | Dec 31, 2019 | $54.11M | -27.9% |
| 2018 | Dec 31, 2018 | $75.02M | -75.2% |
| 2017 | Dec 29, 2017 | $302.04M | +11.2% |
| 2016 | Dec 30, 2016 | $271.53M | – |
See a number that looks wrong?